The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | Understanding patient perspectives in CLL treatment
Brian Koffman, MDCM (retired), MS Ed, CLL Society, Inc., Chula Vista, CA, shares his insights into patient perspectives on the changing chronic lymphocytic leukemia (CLL) treatment landscape. Dr Koffman reports that a study found that patients were more likely to be aware of 17p status than complex karyotype or notch-1 status and that despite more than half of patients self-reporting an understanding of measurable residual disease (MRD), a significant proportion expressed a preference for MRD testing at clinically inappropriate times. Other findings include continued remission being viewed as the most important benefit of limited-duration therapy. As CLL treatment evolves to increasingly incorporate MRD testing, extra care needs to be taken to ensure that CLL patients are properly informed on CLL disease management. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
